Gilde Healthcare leads £6 million ($9.4 million) financing round of Digital Health company Qinec - Gilde Healthcare

Gilde Healthcare leads £6 million ($9.4 million) financing round of Digital Health company Qinec

9. Juni 2015

London – Qinec, a pioneer in Personalized Healthcare Management, today announced that it has secured £6 million in Series B funding, led by Gilde Healthcare. Existing investors Amadeus Capital Partners and Archimedia participated as well.

Qinec will use the funding to scale the team and further expand within a Healthcare IT market segment predicted to be worth over $1.3 billion.

Qinec, which counts Alliance Medical and Optegra Eye Health Care amongst its customers, uses real-time data to personalize the patient journey resulting in optimal outcomes for patients, providers and payers whilst simultaneously reducing cost. Its cloud-based Software as a Service (SaaS) platform today supports millions of patient journeys a year across Europe.

As part of the investment, Janke Dittmer, partner at Gilde Healthcare, joins the Board as a Non-Executive Director and Erik Masing as an Advisor. Additionally, Qinec is strengthening its executive team with the introduction of Andrew Wyatt as Chief Operating Officer. Andrew brings a depth of experience in successfully scaling software and SaaS businesses, including BroadSoft Inc (NASDAQ: BSFT) where he was VP Strategy and Apertio Ltd where he was Chief Product Operations Officer and interim CEO.

About Qinec
Qinec is a UK-based digital health company providing Personalized Healthcare Management (PHM) solutions. The company’s cloud-based SaaS platform uses real time data to orchestrate the patient journey to achieve optimal outcomes for patients, providers and payers at lower cost.
Managing millions of patients a year across Europe, Qinec tailors processes and optimizes clinical and administrative workflows across every specialty of outpatient care. For more information about Qinec please visit www.qinec.com.

About Gilde Healthcare
Gilde Healthcare (Utrecht, The Netherlands and Cambridge, Massachusetts, US) is a private equity investor focused on fast growing healthcare businesses. It manages €550 million across two business lines. The Gilde Healthcare Technology funds target companies developing home & digital health solutions, medical devices and therapeutics in Europe and the US. The Gilde Healthcare Services funds focus on healthcare service providers, such as specialist clinics, elderly care, primary care and other service providers in the Benelux and Germany.
For a list of Gilde’s portfolio companies please visit the website at www.gildehealthcare.com.

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
21. März 2024

Gilde Healthcare veräussert RAD-x an ein konsortium aus Swiss Life Asset Managers und Vesper Infrastructure Fund I

Gilde Healthcare´s Private Equity Fund (“Gilde Healthcare”), ein auf das Gesundheitswesen spezialisierter Investor, hat eine bindende Vereinbarung über den Verkauf seiner Mehrheitsbeteiligung an RAD-x an ein Konsortium aus Swiss Life Asset Managers und Vesper Next...
18. März 2024

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V.,...
29. Februar 2024